Obesity-Related Chronic Inflammation and Cerebro-Metabolic Disease

doi:10.3969/j.issn.1673-5765.2024.02.003

Abstract

Abstract: Cerebrovascular disease has become the second cause of death worldwide, and its risk is mainly attributed to metabolic disorders. This paper reviewed the pathogenesis of obesity-related chronic inflammation and cerebro-metabolic disease. The aggregation of immune cells, heightened secretion of pro-inflammatory factors and vascular endothelial injury are important pathogenic mechanisms of cerebro-metabolic disease in obesity state. New and effective prevention and treatment strategies such as lifestyle intervention, drug immunotherapy and weight reduction anti-inflammatory therapy targeting inflammation are expected to provide reference for reducing the incidence of cerebro-metabolic diseases while enhancing both patient survival rates and quality of life.

Key words: Obesity; Chronic inflammation; Cerebro-metabolic disease; Adipose tissue macrophage; Anti-inflammatory therapy

摘要： 脑血管病目前已成为全球第二大死亡原因，其发病风险主要归因于代谢紊乱。本文就肥胖相关慢性炎症与代谢性脑血管病的发病机制进行综述。肥胖状态下免疫细胞聚集、促炎因子分泌增加、血管内皮损伤等是代谢性脑血管病的重要致病机制。以炎症为治疗靶点的生活方式干预、药物免疫治疗及减重抗炎治疗等新型、有效的防治策略，有望为降低代谢性脑血管病的发病率，提高患者的生存率和生活质量提供参考依据。

关键词: 肥胖; 慢性炎症; 代谢性脑血管病; 脂肪相关巨噬细胞; 抗炎治疗

CLC Number:

LIANG Xiaoxue, GUO Li. Obesity-Related Chronic Inflammation and Cerebro-Metabolic Disease[J]. Chinese Journal of Stroke, 2024, 19(2): 138-144.

梁小雪, 郭黎. 肥胖相关慢性炎症与代谢性脑血管病[J]. 中国卒中杂志, 2024, 19(2): 138-144.

References

[1] HENDERSON S J，WEITZ J I，KIM P Y. Fibrinolysis：strategies to enhance the treatment of acute ischemic stroke[J]. J Thromb Haemost，2018，16（10）：1932-1940.
[2] TSAO C W，ADAY A W，ALMARZOOQ Z I，et al. Heart disease and stroke statistics—2022 update：a report from the American Heart Association[J/OL]. Circulation，2022，145（8）：e153-e639[2023-11-01]. https://doi.org/10.1161/CIR.0000000000001052.
[3] 许杰，王拥军. 代谢性脑血管病：概念、方法、挑战和未来方向[J]. 中国卒中杂志，2023，18（6）：617-627.
XU J，WANG Y J. Cerebro-metabolic disease：concept，method，challenge and future directions[J]. Chin J Stroke，2023，18（6）：617-627.
[4] GUILHERME A，HENRIQUES F，BEDARD A H，et al. Molecular pathways linking adipose innervation to insulin action in obesity and diabetes mellitus[J]. Nat Rev Endocrinol，2019，15（4）：207-225.
[5] HALL J E，DO CARMO J M，DA SILVA A A，et al. Obesity，kidney dysfunction and hypertension：mechanistic links[J]. Nat Rev Nephrol，2019，15（6）：367-385.
[6] NEELAND I J，POIRIER P，DESPRÉS J P. Cardiovascular and metabolic heterogeneity of obesity：clinical challenges and implications for management[J]. Circulation，2018，137（13）：1391-1406.
[7] PAN X F，WANG L M，PAN A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol，2021，9（6）：373-392.
[8] KOENEN M，HILL M A，COHEN P，et al. Obesity，adipose tissue and vascular dysfunction[J]. Circ Res，2021，128（7）：951-968.
[9] LOMBARDO M，FERACO A，BELLIA C，et al. Influence of nutritional status and physical exercise on immune response in metabolic syndrome[J]. Nutrients，2022，14（10）：2054.
[10] 中华医学会内分泌学分会，中华中医药学会糖尿病分会，中国医师协会外科医师分会肥胖和糖尿病外科医师委员会，等. 基于临床的肥胖症多学科诊疗共识（2021年版）[J]. 中华肥胖与代谢病电子杂志，2021，7（4）：211-226.
Chinese Society of Endocrinology，Diabetes Society of China Association of Chinese Medicine，Chinese Society for Metabolic and Bariatric Surgery，et al. Multidisciplinary clinical consensus on diagnosis and treatment of obesity（2021 edition）[J]. Chinese Journal of Obesity and Metabolic Diseases（Electronic Edition），2021，7（4）：211-226.
[11] FRITHIOFF-BØJSØE C，LUND M A V，LAUSTEN-THOMSEN U，et al. Leptin，adiponectin，and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity[J]. Pediatr Diabetes，2020，21（2）：194-202.
[12] RAFEY M F，ABDALGWAD R，O’SHEA P M，et al. Changes in the leptin to adiponectin ratio are proportional to weight loss after meal replacement in adults with severe obesity[J/OL]. Front Nutr，2022，9：845574[2023-11-01]. https://doi.org/10.3389/fnut.
2022.845574.
[13] MASSIER L，JALKANEN J，ELMASTAS M，et al. An integrated single cell and spatial transcriptomic map of human white adipose tissue[J]. Nat Commun，2023，14（1）：1438.
[14] HOTAMISLIGIL G S. Inflammation，metaflammation and immunometabolic disorders[J]. Nature，2017，542（7640）：177-185.
[15] WEISBERG S P，MCCANN D，DESAI M，et al. Obesity is associated with macrophage accumulation in adipose tissue[J]. J Clin Invest，2003，112（12）：1796-1808.
[16] FUCHS A，SAMOVSKI D，SMITH G I，et al. Associations among adipose tissue immunology，inflammation，exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease[J/OL]. Gastroenterology，2021，161（3）：968-981，e1-e12[2023-11-01]. https://doi.org/10.1053/j.
gastro.2021.05.008.
[17] MAURIZI G，DELLA GUARDIA L，MAURIZI A，et al. Adipocytes properties and crosstalk with immune system in obesity-related inflammation[J]. J Cell Physiol，2018，233（1）：88-97.
[18] CHAVAKIS T，ALEXAKI V I，FERRANTE A W，Jr. Macrophage function in adipose tissue homeostasis and metabolic inflammation[J]. Nat Immunol，2023，24（5）：757-766.
[19] HILL D A，LIM H W，KIM Y H，et al. Distinct macrophage populations direct inflammatory versus physiological changes in adipose tissue
[J/OL]. Proc Natl Acad Sci U S A，2018，115（22）：E5096-E5105[2023-11-01]. https://doi.org/10.1073/pnas.
1802611115.
[20] NISHIMURA S，MANABE I，NAGASAKI M，et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity[J]. Nat Med，2009，15（8）：914-920.
[21] WINER S，CHAN Y，PALTSER G，et al. Normalization of obesity-associated insulin resistance through immunotherapy[J]. Nat Med，2009，15（8）：921-929.
[22] FEUERER M，HERRERO L，CIPOLLETTA D，et al. Lean，but not obese，fat is enriched for a unique population of regulatory T cells that affect metabolic parameters[J]. Nat Med，2009，15（8）：930-939.
[23] LEE Y S，OLEFSKY J. Chronic tissue inflammation and metabolic disease[J]. Genes Dev，2021，35（5/6）：307-328.
[24] ZATTERALE F，LONGO M，NADERI J，et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes[J/OL]. Front Physiol，2019，10：1607[2023-11-01]. https://doi.org/10.3389/fphys.2019.01607.
[25] KIM K A，SHIN D，KIM J H，et al. Role of autophagy in endothelial damage and blood-brain barrier disruption in ischemic stroke[J]. Stroke，2018，49（6）：1571-1579.
[26] WILHELM I，NYÚL-TÓTH Á，KOZMA M，et al. Role of pattern recognition receptors of the neurovascular unit in inflamm-aging[J/OL]. Am J Physiol Heart Circ Physiol，2017，313（5）：H1000-
H1012[2023-11-01]. https://doi.org/10.1152/ajpheart.
00106.2017.
[27] REGENHARDT R W，DAS A S，LO E H，et al. Advances in understanding the pathophysiology of lacunar stroke：a review[J]. JAMA Neurol，2018，75（10）：1273-1281.
[28] SIFAT A E，VAIDYA B，ABBRUSCATO T J. Blood-brain barrier protection as a therapeutic strategy for acute ischemic stroke[J]. AAPS J，2017，19（4）：957-972.
[29] DA FONSECA A C，MATIAS D，GARCIA C，et al. The impact of microglial activation on blood-brain barrier in brain diseases[J/OL]. Front Cell Neurosci，2014，8：362[2023-11-01]. https://doi.org/10.3389/fncel.
2014.00362.
[30] CRISPINO M，TRINCHESE G，PENNA E，et al. Interplay between peripheral and central inflammation in obesity-promoted disorders：the impact on synaptic mitochondrial functions[J]. Int J Mol Sci，2020，21（17）：5964.
[31] YOUWAKIM J，GIROUARD H. Inflammation：a mediator between hypertension and neurodegenerative diseases[J]. Am J Hypertens，2021，34（10）：1014-1030.
[32] SACHAN A，SINGH A，SHUKLA S，et al. Serum adipocytokines levels and their association with insulin sensitivity in morbidly obese individuals undergoing bariatric surgery[J]. J Obes Metab Syndr，2020，29（4）：303-312.
[33] BIANCONI V，SAHEBKAR A，ATKIN S L，et al. The regulation and importance of monocyte chemoattractant protein-1[J]. Curr Opin Hematol，2018，25（1）：44-51.
[34] LI G L，BARRETT E J，BARRETT M O，et al. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway[J]. Endocrinology，2007，148（7）：3356-3363.
[35] EID R A，ALKHATEEB M A，EL-KOTT A F，et al. A high-fat diet rich in corn oil induces cardiac fibrosis in rats by activating JAK2/STAT3 and subsequent activation of ANG Ⅱ/TGF-1β/Smad3 pathway：the role of ROS and IL-6 trans-signaling
[J/OL]. J Food Biochem，2019，43（8）：e12952[2023-11-01]. https://doi.org/10.1111/jfbc.12952.
[36] WU L，QIAN L L，ZHANG L，et al. Fibroblast growth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events
[J/OL]. JAHA，2020，9（11）：e015226[2023-11-01].
https://doi.org/10.1161/JAHA.119.015226.
[37] WANG G，HAN B H，ZHANG R X，et al. C1q/TNF-
related protein 9 attenuates atherosclerosis by inhibiting hyperglycemia-induced endothelial cell senescence through the AMPKα/KLF4 signaling pathway[J/OL]. Front Pharmacol，2021，12：758792[2023-11-01]. https://doi.org/10.3389/fphar.
2021.758792.
[38] LEE L Y，OLDHAM W M，HE H，et al. Interferon-γ impairs human coronary artery endothelial glucose metabolism by tryptophan catabolism and activates fatty acid oxidation[J]. Circulation，2021，144（20）：1612-1628.
[39] LIU L H，SHI Z H，JI X H，et al. Adipokines，adiposity，and atherosclerosis[J]. Cell Mol Life Sci，2022，79（5）：272.
[40] GANGULY R，KHANAL S，MATHIAS A，et al. TSP-1（thrombospondin-1）deficiency protects ApoE-/- mice against leptin-induced atherosclerosis
[J/OL]. Arterioscler Thromb Vasc Biol，2021，41（2）：e112-e127[2023-11-01]. https://doi.org/10.1161/ATVBAHA.
120.314962.
[41] KHOUKAZ H B，JI Y，BRAET D J，et al. Drug targeting of plasminogen activator inhibitor-1 inhibits metabolic dysfunction and atherosclerosis in a murine model of metabolic syndrome[J]. Arterioscler Thromb Vasc Biol，2020，40（6）：1479-1490.
[42] TU W J，QIU H C，LIU Y K，et al. Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke[J]. Cardiovasc Diabetol，2020，19（1）：125.
[43] SEO J B，RIOPEL M，CABRALES P，et al. Knockdown of Ant2 reduces adipocyte hypoxia and improves insulin resistance in obesity[J]. Nat Metab，2019，1（1）：86-97.
[44] SCHÖDEL J，RATCLIFFE P J. Mechanisms of hypoxia signalling：new implications for nephrology[J]. Nat Rev Nephrol，2019，15（10）：641-659.
[45] SEMENZA G L. Pharmacologic targeting of hypoxia-inducible factors[J/OL]. Annu Rev Pharmacol Toxicol，2019，59：379-403[2023-11-01]. https://doi.org/10.1146/annurev-pharmtox-010818-021637.
[46] KOHUT M L，MCCANN D A，RUSSELL D W，et al. Aerobic exercise，but not flexibility/resistance exercise，reduces serum IL-18，CRP，and IL-6 independent of beta-blockers，BMI，and psychosocial factors in older adults[J]. Brain Behav Immun，2006，20（3）：201-209.
[47] DONGES C E，DUFFIELD R，DRINKWATER E J. Effects of resistance or aerobic exercise training on interleukin-6，C-reactive protein，and body composition[J]. Med Sci Sports Exerc，2010，42（2）：304-313.
[48] ČÍŽKOVÁ T，ŠTĚPÁN M，DAĎOVÁ K，et al. Exercise training reduces inflammation of adipose tissue in the elderly：cross-sectional and randomized interventional trial[J/OL]. J Clin Endocrinol Metab，2020，105（12）：e4510-e4526[2023-11-01]. https://doi.org/10.1210/clinem/dgaa630.
[49] GONZALO-ENCABO P，MALDONADO G，VALADÉS D，et al. The role of exercise training on low-grade systemic inflammation in adults with overweight and obesity：a systematic review[J]. Int J Environ Res Public Health，2021，18（24）：13258.
[50] HU Y，YANG Y，ZHANG M，et al. Intermittent fasting pretreatment prevents cognitive impairment in a rat model of chronic cerebral hypoperfusion[J]. J Nutr，2017，147（7）：1437-1445.
[51] HU H J，GARCIA-BARRIO M，JIANG Z S，et al. Roles of perivascular adipose tissue in hypertension and atherosclerosis[J]. Antioxid Redox Signal，2021，34（9）：736-749.
[52] VAN BEUSECUM J P，MORENO H，HARRISON D G. Innate immunity and clinical hypertension[J]. J Hum Hypertens，2022，36（6）：503-509.
[53] FEIJÓO-BANDÍN S，ARAGÓN-HERRERA A，MORAÑA-FERNÁNDEZ S，et al. Adipokines and inflammation：focus on cardiovascular diseases[J]. Int J Mol Sci，2020，21（20）：7711.
[54] ZHUGE F，NI Y H，NAGASHIMADA M，et al. DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization[J]. Diabetes，2016，65（10）：2966-2979.
[55] KRUMBECK J A，RASMUSSEN H E，HUTKINS R W，et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics[J]. Microbiome，2018，6（1）：121.
[56] WADDEN T A，BAILEY T S，BILLINGS L K，et al. Effect of subcutaneous semaglutide vs. placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity：the STEP 3 randomized clinical trial[J]. JAMA，2021，325（14）：1403-1413.
[57] WILSON J M，LIN Y Z，LUO M J，et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes：a post hoc analysis[J]. Diabetes Obes Metab，2022，24（1）：148-153.